Body Vision Medical Receives Regulatory Approval for LungVision® in Australia, Expanding Access to AI-Driven Advanced Imaging for Lung Cancer Diagnosis
MT WAVERLEY, VIC – March 12, 2025
ParagonCare the exclusive distribution partner of BV, is excited to announce that Body Vision Medical’s LungVision® AI-driven advanced imaging system has received regulatory approval from the Therapeutic Goods Administration (TGA) in Australia.
Body Vision Medical’s innovative technology ensures that hospitals and clinics throughout Australia will now have access to state-of-the-art AI-driven imaging solutions, reinforcing the shared commitment to advancing lung cancer diagnosis and treatment.
"We are excited to welcome Body Vision Medical’s technology to our portfolio, as it strengthens our commitment to advancing augmented lung and respiratory medicine through cutting-edge AI. Body Vision's real-time imaging technology offers remarkable opportunities, significantly enhancing the chances for earlier cancer detection and ultimately improves lung cancer survival rates." – Tiffany Chiew, General Manager, Capital and Service.
Lung cancer remains the leading cause of cancer-related deaths in Australia, with an estimated 14,500 new cases diagnosed annually. With the Australian Government Department of Health and Aged Care launching the National Lung Cancer Screening Program (NLCSP) to detect lung cancer at earlier stages, there is an increasing need for a definitive diagnostic pathway for patients with suspicious pulmonary nodules (SPNs).
LungVision®, an AI-driven imaging system that transforms any C-arm into a 3D imaging system, empowers physicians with real-time navigation and enhanced visualisation to achieve more precise and accurate bronchoscopic biopsies. By enabling more confident diagnoses, LungVision® supports the clinical goals of the NLCSP and can enhance patient outcomes. ParagonCare is proud to partner with Body Vision Medical to support this national initiative by providing solutions that align with evolving screening guidelines and clinical practices.
“This approval represents a major step forward in our global mission to transform lung cancer care,” said Matt Baker, CEO at Body Vision Medical. “We are thrilled to partner with ParagonCare to make LungVision® available in Australia and New Zealand, where the need for accurate, early-stage lung cancer diagnosis has never been more urgent.”
ParagonCare will be launching LungVision® to the Australian market at the TSANZSRS the combined meeting for the Thoracic Society of Australia and New Zealand and the Australian and New Zealand Society of Respiratory Science, held from 21st -25th March in Adelaide, South Australia.
We invite you to visit the ParagonCare booth (#54) to meet our team, experience a live demo, and discuss how LungVision® can contribute to the success of the NLCSP and your lung cancer screening efforts.
For more information about LungVision® and its availability in Australia and New Zealand, please contact the ParagonCare team via the ParagonCare website or below contacts.
Visit bodyvisionmedical.com to learn more and connect with us on LinkedIn.
ParagonCare Media Contact:
Kylie Inserra
Group Communications & Branding Lead
T 1300 726 226
E kylie.inserra@paragoncare.com.au
W paragoncare.com.au
ParagonCare Customer Contact:
Tiffany Chiew
General Manager Capital & Service
T 1800 228 118
E tiffany.chiew@paragoncare.com.au
W paragoncare.com.au